The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Due to the inherent low immunogenicity and immunosuppressive tumor microenvironment (TME) of malignant cancers, the clinical efficacy and application of tumor immunotherapy have been limited. Herein, a bimetallic drug‐gene co‐loading network (Cu/ZIF‐8@U‐104@siNFS1‐HA) is developed that increased the intracellular labile iron pool (LIP) and enhanced the weakly acidic TME by co‐suppressing the dual...
Photodynamic therapy (PDT) is extensively investigated for tumor therapy in the clinic. However, the efficacy of PDT is severely limited by the tissue penetrability of light, short effective half‐life and radius of reactive oxygen species (ROS), and the weak immunostimulatory effect. In this study, a glutathione (GSH)‐activatable nano‐photosensitizer is developed to load with arachidonic acid (AA)...
Design of effective nanodrugs to modulate the immunosuppression of tumor microenvironment is a desirable approach to boost the clinical tumor‐therapeutic effect. Supramolecular nanomicelles PolyMN‐TO‐8, which are constructed by self‐assembling supramolecular host MTX‐MPEG2000, guest NPX‐2S, and TO‐8 through hydrophobic forces, have excellent stability and responsiveness to carboxylesterase and glutathione...
Reprogramming the immunologically “cold” environment of solid tumors is currently becoming the mainstream strategy to elicit powerful and systemic anticancer immunity. Here, a facile and biomimetic nano‐immunnoactivator (CuS/Z@M4T1) is detailed by engineering a Zn2+‐bonded zeolitic imidazolate framework‐8 (ZIF‐8) with CuS nanodots (NDs) and cancer cell membrane for amplified near‐infrared‐II (NIR‐II)...
Immunogenic cell death (ICD) can activate the body's immune system via dead cell antigens to achieve immunotherapy. Currently, small molecule drugs have been used for ICD treatment in clinical, however, how to precisely control the induced ICD while treating tumors is of great significance for improving therapeutic efficacy. Based on this, a sono/light dual response strategy to tumor therapy and activation...
Bismuth‐Based Semiconductors
Degradable bismuth semiconductor's properties are controlled by topological synthesis, which carries ivermectin under ultrasound and light action to produce reactive oxygen species (ROS) and heat, induce tumors to realize immunogenic cell death, and further activate T cells to achieve synergistic immunotherapy. More details can be found in article number 2304032 by Yuhao...
Breaking immunosuppressive tumor microenvironment (TME) has unique effects on inhibiting tumor growth and recurrence. Here, an endoplasmic reticulum (ER) targeted PdPtCu nanozyme (PNBCTER) is prepared to boost immunotherapy. First, PNBCTER has three kinds of enzyme activities, including catalase (CAT), glutathione oxidase (GSHOx), and peroxidase (POD)‐like activities, which can reshape the TME. Second,...
Triple‐Negative Breast Cancer Chemoimmunotherapy
In article number 2302834, Kaipei Luo, Xiaofang Li, and co‐workers develop a LyP‐1 and chondroitin sulfate dual‐modified liposome co‐loading paclitaxel and cryptotanshinone. The liposome enhances cellular uptake via p32/CD44 dual receptor‐mediated endocytosis, and achieves potent triple‐negative breast cancer chemoimmunotherapy through inducing immunogenic...
Immunotherapy gains increasing focus in treating triple‐negative breast cancer (TNBC), while its efficacy is greatly restricted owing to low tumor immunogenicity and immunosuppressive tumor microenvironment (ITM). Herein, a LyP‐1 and chondroitin sulfate (CS) dual‐modified liposome co‐loaded with paclitaxel (PTX) and cryptotanshinone (CTS), namely CS/LyP‐1‐PC Lip, is engineered for TNBC chemoimmunotherapy...
Development of intelligent nanoplatforms that can simultaneously target multiple factors associated with tumor growth and metastasis remains an extreme challenge. Here, an intelligent dendritic nanodevice incorporating both copper sulfide nanoparticles (CuS NPs) and 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA, a vascular disrupting agent) within the dendrimer internal cavities and surface modified...
Chemotherapeutics can induce immunogenic cell death (ICD) by triggering autophagy and mediate antitumor immunotherapy. However, using chemotherapeutics alone can only cause mild cell‐protective autophagy and be incapable of inducing sufficient ICD efficacy. The participation of autophagy inducer is competent to enhance autophagy, so the level of ICD is promoted and the effect of antitumor immunotherapy...
Enhanced Tumor Immunotherapies
Tailor‐made polymeric nanoparticles with the function of autophagy cascade amplification due to the co‐delivery of autophagy inducer STF‐62247 and antitumor drug epirubicin, which could assist cell uptake and tumor penetration with the help of arginine and promote immunogenic cell death by the enhancement of autophagy for the best tumor immunotherapy effect. More details...
Synergetic Prostate Cancer Therapies
In article number 2207077, Li Zhang, Yunjiao Zhang, Chaozhao Liang, and co‐workers propose intratumoral implantation of micromagnets to actively attract intravenously‐injected magnetic PEGylated manganese‐zinc ferrite nanocrystals (PMZFNs) from blood vessels into tumor tissue. PMZFNs exert relatively durable tumoricidal effects by inducing ferroptotic/immunogenic...
Therapeutic efficacy for prostate cancer is highly restricted by insufficient drug accumulation and the resistance to apoptosis and immunogenic cell death (ICD). Although enhanced permeability and retention (EPR) effect of magnetic nanomaterials could benefit from external magnetic field, it falls off rapidly with increased distance from magnet surface. Considering the deep location of prostate in...
Photodynamic therapy (PDT) can generate reactive oxygen species (ROS) to cause cell apoptosis and induce immunogenic cell death (ICD) to activate immune response, becoming a promising antitumor modality. However, the overexpressions of indoleamine 2,3‐dioxygenase (IDO) and programmed cell death ligand 1 (PD‐L1) on tumor cells would reduce cytotoxic T cells infiltration and inhibit the immune activation...
Cancer Immunotherapy
In article number 2201298, Houjie Liang, Songtao Yu, and co‐workers report how localized cancer phototherapy on primary tumors with nanosized small molecule‐albumin complexes by in vivo self‐assembly, ultimately trigger sufficient antitumor immune responses to effectively suppress growths of distant metastatic tumors.
Cancer immunotherapy has great potential in tumor eradication and metastasis suppression. However, systemic administration of immune adjuvants and inadequate specificity in cancer treatment, lead to restricted therapeutic benefits and potential immune‐related side effects in clinical settings. In this report, the synthesis of various lengths of heptamethine cyanine small molecules to act as multifunctional...
The endoplasmic reticulum (ER) in cancer cells has been considered as a pharmacological target. Still, the effects of a ER‐targeted system remain less investigated, due to the fact that most chemo‐drugs take actions in the nucleus. Here, it is demonstrated that ER‐targeted delivery of doxorubicin (DOX), a typically nucleus‐tropic‐and‐acting agent, attenuates its original effect on cytotoxicity while...
Colorectal cancer (CRC) ranks as the third common and the fourth lethal cancer type worldwide. Immune checkpoint blockade therapy demonstrates great efficacy in a subset of metastatic CRC patients, but precise activation of the antitumor immune response at the tumor site is still challenging. Here a versatile prodrug nanoparticle for second near‐infrared (NIR‐II) fluorescence imaging‐guided combinatory...
Nanoparticle‐based tumor immunotherapy has emerged to show great potential for simultaneously regulating the immunosuppressive tumor microenvironment, reducing the unpleasant side effects, and activating tumor immunity. Herein, an excipient‐free glutathione/pH dual‐responsive prodrug nanoplatform is reported for immunotherapy, simply by sequentially liberating 5‐aminolevulinic acid and immunogenically...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.